Aerie Pharmaceuticals (NASDAQ:AERI) Downgraded by StockNews.com to Hold

StockNews.com downgraded shares of Aerie Pharmaceuticals (NASDAQ:AERIGet Rating) from a buy rating to a hold rating in a research report report published on Tuesday morning.

Other research analysts have also issued research reports about the company. HC Wainwright lowered Aerie Pharmaceuticals from a buy rating to a neutral rating in a report on Wednesday, August 24th. Truist Financial lowered Aerie Pharmaceuticals from a buy rating to a hold rating in a research note on Wednesday, August 24th. Cantor Fitzgerald lowered Aerie Pharmaceuticals from an overweight rating to a neutral rating and dropped their price target for the stock from $30.00 to $15.25 in a research note on Tuesday, August 23rd. Stifel Nicolaus downgraded Aerie Pharmaceuticals from a buy rating to a hold rating and set a $15.00 price target on the stock. in a report on Tuesday, August 23rd. Finally, Needham & Company LLC downgraded Aerie Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, August 23rd. Seven research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, Aerie Pharmaceuticals currently has an average rating of Hold and a consensus price target of $16.90.

Aerie Pharmaceuticals Price Performance

Shares of AERI opened at $15.23 on Tuesday. The stock has a market cap of $752.62 million, a PE ratio of -19.78 and a beta of -0.06. The business has a 50-day simple moving average of $15.18 and a two-hundred day simple moving average of $10.84. Aerie Pharmaceuticals has a 12-month low of $4.81 and a 12-month high of $15.37.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Great West Life Assurance Co. Can bought a new stake in shares of Aerie Pharmaceuticals during the 3rd quarter worth approximately $27,000. US Bancorp DE grew its stake in Aerie Pharmaceuticals by 174.4% during the 1st quarter. US Bancorp DE now owns 3,685 shares of the company’s stock valued at $34,000 after purchasing an additional 2,342 shares during the last quarter. Longfellow Investment Management Co. LLC purchased a new stake in shares of Aerie Pharmaceuticals in the third quarter worth about $36,000. Advisor Group Holdings Inc. boosted its stake in shares of Aerie Pharmaceuticals by 33.9% in the first quarter. Advisor Group Holdings Inc. now owns 6,863 shares of the company’s stock worth $62,000 after buying an additional 1,739 shares during the last quarter. Finally, Amalgamated Bank purchased a new stake in shares of Aerie Pharmaceuticals in the first quarter worth about $63,000. Institutional investors own 95.94% of the company’s stock.

Aerie Pharmaceuticals Company Profile

(Get Rating)

Aerie Pharmaceuticals, Inc, a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension.

Recommended Stories

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.